Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab.

Click to increase image sizeClick to decrease image size Disclosure statementNo potential conflict of interest was reported by the author(s).Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.